New directions for drug discovery in psychiatric disease

Dialogues in Clinical Neuroscience

Volumn 4, Issue 4, 2002, Pages 336-341

  Spedding, Michael ^a   Sebban, Claude ^b   Perret, Laurent ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^b HÔPITAL CHARLES FOIX   (France)

Author keywords

Clozapine; Drug discovery; EEG; Phencyclidine; Schizophrenia

Indexed keywords

1 (4 AMINOPHENYL) 3,4 DIHYDRO 4 METHYL 3 METHYLCARBAMOYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; ALPHA ADRENERGIC RECEPTOR; CHLORPROMAZINE; CLOZAPINE; DIZOCILPINE; DOPAMINE RECEPTOR; HALOPERIDOL; KETAMINE; MODAFINIL; OLANZAPINE; PHENCYCLIDINE; RISPERIDONE;

ALPHA RHYTHM; ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL RESEARCH; COGNITION; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; ELECTROENCEPHALOGRAPHY; HIPPOCAMPUS; HUMAN; HUMAN GENOME; IN VIVO STUDY; MENTAL DISEASE; MOLECULAR CLONING; MOTOR PERFORMANCE; NONHUMAN; PREFRONTAL CORTEX; RAT; REM SLEEP; SCHIZOPHRENIA; SENSORIMOTOR CORTEX; THETA RHYTHM;

EID: 0037993807     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (21)

1. 2-adrenoceptor subtypes. Br J Pharmacol. 1993;109:371-378.
2. Spedding M, Dacquet C. Transduction is a major factor influencing receptor characterization. Ann N Y Acad Sci. 1996;812:29-40.
3. Jacoby E, Raimbaud E, Ollivier S, Michel A, Spedding M. The molecular architecture of ligands and receptor mutation experiments reveal a three-binding-site hypothesis for the interaction of ligands with monoamine G-protein-coupled receptors: implications for combinatorial ligand design. Quant Struct-Act Relat. 1999;18:561-572.
4. Goldman-Rakic PS. Prefrontal cortical dysfunction in schizophrenia: relevance of working memory. In: Carroll BJ, Barrett JE, eds. Psychopathology and the Brain. New York, NY: Raven; 1991:1-23.
5. 1 receptors in prefrontal cells and circuits. Brain Res Rev. 2000;31:295-301.
6. Crespo-Facorro B, Kim JJ, Andreasen NC, O'Leary DS, Magnotta V. Regional frontal abnormalities in schizophrenia: a quantitative gray matter volume and cortical surface size study. Biol Psychiatry. 2000;48:110-119.
7. Young KA, Manaye KF, Liang CL, Hicks PB, German DC. Reduced number of mediodorsal and anterior thalamic neurons in schizophrenia. Biol Psychiatry. 2000;47:944-953.
8. Weinberger DR. On the plausibility of "the neurodevelopment hypothesis" of schizophrenia. Neuropsychopharmacology. 1996;14:1S-11S.
9. Lipska BK, Swerdlow NR, Geyer MA, Jaskiw GE, Braff DL, Weinberger DR. Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology (Berl). 1995;122:35-43.
10. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelly R. Study of a new schizophrenic-like drug: Sernyl. Arch Neurol Psychiatry. 1959;81:363-369.
11. Cohen BD, Rosenbaum G, Luby ED, Gottlieb JS. Comparison of phencyclidine hydrochloride (Sernyl) with other drugs. Simulation of schizophrenic performance with phencyclidine hydrochloride (Sernyl), lysergic acid diethylamide (LSD-25), and amobarbital (Amytal) sodium: II. Symbolic and sequential thinking. Arch Gen Psychiatry. 1962;6:395-401.
12. Allen RM, Young SJ. Phencyclidine-induced psychosis. Am J Psychiatry. 1978;135:1081-1084.
13. Ellison G. The N-methyl-D-aspartate antagonists phencyclidine, ketamine, and dizocilpine as both behavioral and anatomical models of the dementias. Brain Res Rev. 1995;20:250-267.
14. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport. 1995;6:869-872.
15. Malhotra AK, Adler CM, Kennison SD, Elman I, Pickar D, Breier A. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis. A study with ketamine. Biol Psychiatry. 1997;42:664-668.
16. Malhotra AK, Pinals DA, Adler CM, et al. Ketamine-induced exacerbation in psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology. 1997;17:141-149.
17. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1999;20:201-225.
18. Lahti AC, Weiler MA, Michaelidis T, Parwani T, Tamminga CA. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology. 2001;25:455-467.
19. Sebban C, Zhang XQ, Tesolin-Decros B, Millan MJ, Spedding M. Changes in EEG spectral power in the prefrontal cortex of conscious rats elicited by drugs interacting with dopaminergic and noradrenergic transmission. Br J Pharmacol. 1999;128:1045-1054.
20. Sebban C, Tesolin-Decros B, Millan MJ, Spedding M. Contrasting EEG profiles elicited by antipsychotic agents in the prefrontal cortex of the conscious rat: antagonism of the effects of clozapine by modafinil. Br J Pharmacol. 1999;128:1055-1063.
21. Sebban C, Tesolin-Decros S, Ciprian-Ollivier J, Perret L, Spedding M. Effects of phencyclidine (PCP) and MK 801 on the EEGq in the prefrontal cortex of the conscious rats; antagonism by clozapine, and antagonists of AMPA-, alpha(1)- and 5-HT(2A)-receptors. Br J Pharmacol. 2002;135:65-78.